Bosutinib versus placebo for autosomal dominant polycystic kidney disease

V Tesar, K Ciechanowski, Y Pei, I Barash… - Journal of the …, 2017 - journals.lww.com
Overactivation of Src has been linked to the pathogenesis of autosomal dominant polycystic
kidney disease (ADPKD). This phase 2, multisite study assessed the efficacy and safety of
bosutinib, an oral dual Src/Bcr-Abl tyrosine kinase inhibitor, in patients with ADPKD. Patients
with ADPKD, eGFR≥ 60 ml/min per 1.73 m 2, and total kidney volume≥ 750 ml were
randomized 1: 1: 1 to bosutinib 200 mg/d, bosutinib 400 mg/d, or placebo for≤ 24 months.
The primary endpoint was annualized rate of kidney enlargement in patients treated for≥ 2 …